New drug combo may help more kidney cancer patients avoid full kidney removal

This study tests whether giving a combination of two drugs (a PD-L1 inhibitor called TQB2450 and anlotinib) before surgery can shrink complex kidney tumors enough to allow surgeons to remove only the tumor and save the rest of the kidney. About 33 adults with advanced clear cell kidney cancer that is hard to operate on will receive the drugs first, then doctors will check if kidney-sparing surgery becomes possible. The goal is to avoid removing the whole kidney while still controlling the cancer.